Physician profile
Amber D Walker
NPI 1174832042
$2,115.31
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $773 · 2022: $467 · 2023: $653 · 2024: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $604.29 | 2021-2024 | |
| Lilly USA, LLC | $163.64 | 2021-2023 | Mounjaro |
| Amgen INC. | $138.84 | 2022-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $122.40 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $117.13 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $91.35 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $86.38 | 2021-2023 | Nuedexta, Rexulti |
| Sanofi-Aventis U.S. LLC | $78.34 | 2021-2023 | |
| Novo Nordisk INC | $65.44 | 2021-2024 | Wegovy |
| Lundbeck LLC | $63.13 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.83 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.72 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $42.08 | 2021 | |
| Axsome Therapeutics, INC. | $39.35 | 2023 | Auvelity |
| Biogen, INC. | $39.35 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.33 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $37.42 | 2021 | |
| Corcept Therapeutics | $36.75 | 2023-2024 | Korlym |
| Eisai INC. | $34.56 | 2021 | |
| Xeris Pharmaceuticals, INC. | $29.23 | 2021-2023 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $28.23 | 2021-2022 | |
| Abbott Laboratories | $21.74 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $20.07 | 2021 | |
| Astellas Pharma US INC | $14.98 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.20 | 2022 | |
| Genentech USA, INC. | $12.95 | 2022 | |
| Corium, LLC | $12.38 | 2024 | Azstarys |
| Daiichi Sankyo INC. | $12.28 | 2022 | |
| Irhythm Technologies, INC. | $12.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.65 | 2022 | |
| Pfizer INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.